

REMARKS

Applicants hereby elect to prosecute the claims of Group I, claims 1-4 and 22-25 drawn to a method for identifying a patient-specific ratio of two or more therapeutic agents. Within this elected group, the limitations of claims 4 and 25 have been placed into claims 1 and 22 respectively, as, upon reflection, applicants have determined that this level of synergy is desirable.

Claims to the non-elected inventions of Groups III and IV have been canceled.

However, as to Group II, claim 5 has been amended to be dependent from claim 1; it is noted that claim 22, which is included in Group I, also includes the step of preparing the actual pharmaceutical composition; thus, claims 1 and 5 in combination are of essentially the same invention group as claim 22. Making claim 5 dependent on claim 1 makes claims 7-9 redundant and these claims have been canceled.

Similarly, claim 10, which is also in Group II, has been amended to depend from claim 1, again making claims 12-14 redundant. Claim 16 appears redundant with claim 11 and it has been canceled as well.

Thus, applicants request examination of claims 1, 5, 6, 10-12, 15 and 22.

It is believed that with the consolidation of the claim set in terms of the required synergy, thus simplifying the number of claims, it would not constitute an undue burden to examine the claims of what was formerly classified as Groups I and II.

